|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms:Experience with Rifaximin显示文摘AIM:To estimate the prevalence of small intestinal bacterial overgrowth(SIBO) in our geographical area(Western Sicily,Italy) by means of an observational study,and to gather information on the use of locally active,non-absorbable antibiotics for treatment of SIBO.METHODS:Our survey included 115 patients fulfilling the Rome □ criteria for diagnosis of irritable bowel syndrome(IBS);a total of 97 patients accepted to perform a breath test with lactulose(BTLact),and those who had a positive test,received Rifaximin(Normix,Alfa Wassermann) 1200 mg/d for 7 d;3 wk after the end of treatment,the BTLact was repeated.RESULTS:Based on the BTLact results,SIBO was present in about 56% of IBS patients,and it was responsible for some IBS-related symptoms,such as abdominal bloating and discomfort,and diarrhoea.1-wk treatment with Rifaximin turned the BTLact to negative in about 50% of patients and significantly reduced the symptoms,especially in those patients with an alternated constipation/diarrhoea-variant IBS.CONCLUSION:SIBO should be always suspected in patients with IBS,and a differential diagnosis is done by means of a 'breath test'.Rifaximin may represent a valid approach to the treatment of SIBO. | Sergio Peralta Claudia Cottone Tiziana Doveri Piero Luigi Almasio Antonio Craxi | 2009 | World Journal of Gastroenterology2009，15，21： | 19 |
| 2 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 3 | Statin use and non-alcoholic steatohepatitis in at risk individuals显示文摘 | Paola Dongiovanni Salvatore Petta Ville Mannisto Rosellina Margherita Mancina Rosaria Pipitone Vesa Karja Marco Maggioni Pirjo Kakela Olov Wiklund Enrico Mozzi Stefania Grimaudo Dorota Kaminska Raffaela Rametta Antonio Craxi Silvia Fargion Valerio Nobili | 2015 | Journal of Hepatology2015，，3： | 2 |
| 4 | 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines显示文摘 | Calvaruso V Craxi A | 2012 | Liver Int2012，32，1： | 1 |
| 5 | Epidemiology, risk factors and surveillance of bepatocellular carcinoma显示文摘 | Cabibbo G Craxi A | 2010 | Eur Rev Med Pharmacol Sci2010，14，4： | 1 |
| 6 | Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review显示文摘 | Tarantino G Craxi A | 2009 | Liver Int2009，29，1： | 1 |
| 7 | Treatment Options in HBV显示文摘 | CRAXI A ANTONUCCI G CAMMA C | 2006 | J Hepatol(S0168-8278)2006，44，1： | 1 |
| 8 | EASL Clinical Practice Guidelines : Management of hepa- titis C virus infection显示文摘 | Craxi A | 2011 | J 14epato12011，28，： | 1 |
| 9 | Diagnostic approach to liver enzyme elevation显示文摘 | Craxi A Almasio P | 1996 | J Hepatol1996，25，1： | 1 |
| 10 | Diagnostic approach to liver enzyme elevation 显示文摘 | Craxi A Ahnasio P | 1996 | Hepatol1996，，： | 1 |
| 11 | Treatment options in HBV 显示文摘 | Antonio Craxy Giorgio Antonucci Calogero Camma | 2006 | Journal of Hepatology2006，7783，： | 1 |
| 12 | Non-alcoholic fatty liver dis-ease pathogenesis: the present and the future 显示文摘 | Petta S Muratore C Craxi A | 2009 | Dig LiverDis2009，41，9： | 1 |
| 13 | Non-alcoholic fatty liver disease pathogenesis: The present and the future 显示文摘 | Petta S Muratore C Craxi A | 2009 | Digestive and Liver Disease2009，41，9： | 1 |
| 14 | Diagnostic approach to liver enzyme elevation 显示文摘 | Craxi A Almasio P | 1996 | J Hepatol1996，，： | 1 |
| 15 | Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response 显示文摘 | Pagliaro L Craxi A Cammaa C | 1994 | Hepatology1994，19，4： | 1 |
| 16 | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection 显示文摘 | Fried MW Shiffman ML Reddy KR Smith C Marinos G Goncales FL Jr H/iussinger D Diago M Carosi G Dhumeaux D Craxi A Lin A Hoffman J Yu J | 2002 | N Engl J Med2002，347，13： | 1 |
| 17 | Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association显示文摘 | Petta S Craxi A | 2010 | Curr Pharm Des2010，16，： | 1 |
| 18 | Which patients with cirrhosis should undergo endoscopic screening for esophageal varices (EV) detection?显示文摘 | F. Schepis C. Camma D. Niceforo A. Magnano S. Pallio M. Cinquegrani G. D’Amico L. Pasta A. Craxi A. Saitta G. Raimondo | 2001 | Journal of Hepatology2001，，： | 1 |
| 19 | Epidemiology, risk factors and surveillance of hepatoeellular carcinoma显示文摘 | Cabibbo G Craxi A | 2010 | Eur Rev Med Pharmacol Sci2010，14，4： | 1 |
| 20 | Pegylated interferons for chronic hepatitis B显示文摘 | Craxi A Cooksley WG | 2003 | Antiviral Res2003，60，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员